None listed
Conditions
Interventions
Drug : Tabinul Inj.
Dosage : 0.004mg/kg
The number and duration: 20 to 40 minutes before endoscopy
Injection route : Intramuscular
Experimental group : Glycopyrrolate (0.004mg / kg) Intramuscular
Pla
Sponsors
Gachon University Gil Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients receiving the submucosal dissection for the treatment of gastric adenoma or early gastric cancer under conscious sedation
Exclusion criteria
Exclusion criteria: 1) who have hypersensitivity to this drug 2) The argument of this drug contraindications (Glaucoma, obstructive urinary diseases, gastrointestinal obstructive disorders, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis,myasthenia, megacolon of complication of ulcerative colitis) 3) Acute • Chronic hepatitis, acute • chronic renal failure, coronary artery disease, congestive heart failure, arrhythmia, asthma, chronic obstructive pulmonary disease and other disorders in patients with severe systemic 4) not suitable to determine the other researchers determined the patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the presence of hypoxemia due to oropharyngeal secretion;the overall satisfaction of operator;The degree of bronchial secretions;the presence of aspiration;the presence of cough due to oropharyngeal secretion | — |
Secondary
| Measure | Time frame |
|---|---|
| Presence or absence of complications (aspiration pneumonia, perforation, hemorrhage, hypertension, hypotension, palpitations, urinary disorders, etc.) | — |
Countries
Korea, Republic of
Contacts
Public ContactKyoung-Oh Kim
Gachon University of Medicine and Science
Outcome results
None listed